receptor targets raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-04-22. Anything still debated is marked as such rather than presented as settled.
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
| Property | Value | Notes |
|---|---|---|
| 研究代号 | LY3437943 | 文献中常用的实验标识 |
| 药物类别 | 三重受体激动剂 | 靶向GLP-1、GIP与胰高血糖素受体 |
| 开发状态 | 后期临床研究 | 尚未获批上市 |
| 主要研究人群 | 肥胖与2型糖尿病 | 入组条件依试验方案而定 |
| 常见同义词 | 瑞他鲁肽；LY3437943 | 名称拼写可能因语言和出版物而异 |
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
=== Protein quantification === For genes encoding proteins, the expression level can be directly assessed by a number of methods with some clear analogies to the techniques for mRNA quantification. One of the most commonly used methods is to perform a Western blot against the protein of interest. This gives information on the size of the protein in addition to its identity. A sample (often cellular lysate) is separated on a polyacrylamide gel, transferred to a membrane and then probed with an antibody to the protein of interest. The antibody can either be conjugated to a fluorophore or to horseradish peroxidase for imaging and/or quantification. The gel-based nature of this assay makes quantification less accurate, but it has the advantage of being able to identify later modifications to the protein, for example proteolysis or ubiquitination, from changes in size.
=== Lithium === Lithium extraction is more popular due to the high demand of lithium-ion batteries. TBP (Tri-butyl phosphate) and FeCl3 are mostly used to extract lithium from brine (with high Li/Mg ratio). Alternatively, Cyanex 272 was also used to extract lithium. The mechanism of lithium extraction was found differently from other metals, such as cobalt, due to the weak coordinating bonding between lithium ions and extractants.
== Energy sources == Unlike proto-metabolism, the bioenergetic pathways powering modern metabolism are well understood. In early Earth conditions, there were mainly three kinds of energy to support early metabolic pathways: high energy sources to catalyze monomers, lower energy sources to support condensation or polymerization, and energy carriers that support transfer of energy from the environment to metabolic networks. Examples of high energy sources include photochemical energy from ultraviolet light, atmospheric electric discharge, and geological electrochemical energy. These energy sources would support synthesis of biological monomers or feedstocks for proto-metabolism. In contrast, examples of lower energy sources for assembly of more complex molecules include anhydrous heat, mineral-catalyzed synthesis, and sugar-driven reactions. Energy carrier molecules could allow for propagation of the energy through the metabolic networks likely resembled modern energy carriers including ATP and NADH. Both energy carriers are nucleotide-based molecules and likely originated early in metabolism.
{\displaystyle \int \limits _{\partial \Omega }\left(\mu {\frac {\partial \mathbf {u} }{\partial {\hat {\mathbf {n} }}}}-p{\hat {\mathbf {n} }}\right)\cdot \mathbf {v} =\underbrace {\int \limits _{\Gamma _{D}}\left(\mu {\frac {\partial \mathbf {u} }{\partial {\hat {\mathbf {n} }}}}-p{\hat {\mathbf {n} }}\right)\cdot \mathbf {v} } _{\mathbf {v} =\mathbf {0} {\text{ on }}\Gamma _{D}\ }+\int \limits _{\Gamma _{N}}\underbrace {{\vphantom {\int \limits _{\Gamma _{N}}}}\left(\mu {\frac {\partial \mathbf {u} }{\partial {\hat {\mathbf {n} }}}}-p{\hat {\mathbf {n} }}\right)} _{=\mathbf {h} {\text{ on }}\Gamma _{N}}\cdot \mathbf {v} =\int \limits _{\Gamma _{N}}\mathbf {h} \cdot \mathbf {v} .}
Afghanistan: The Foreign Ministry stipulated that the Assad regime was the "cause of war and instability" and congratulated Tahrir al-Sham. Canada: Prime Minister Justin Trudeau said that the fall of the Assad dictatorship "ends decades of brutal oppression" and said that Canada is monitoring the transition closely. China: The Foreign Ministry stated that it "is closely following the development of the situation in Syria and hopes that Syria returns to stability as soon as possible" and urged all parties to ensure the safety of Chinese citizens in Syria. European Union: EU foreign policy chief Kaja Kallas called the end of Assad's rule a "positive and long-awaited development" and stated she was in close contact with regional ministers. She emphasized that rebuilding Syria would be "long and complicated". France: President Emmanuel Macron commented on social media: "The barbaric state has fallen. At last. I pay tribute to the Syrian people, to their courage, to their patience." He added that France would remain committed to security in the Middle East. Germany: Foreign Minister Annalena Baerbock described the end of the Assad regime as "a big relief for millions of people in Syria" while warning that "the country must not fall into the hands of other radicals". Indonesia: The Ministry of Foreign Affairs reported that the Embassy of Indonesia in Damascus attacked by stray bullets from the Syrian Opposition Forces and causing minor damages to the building on 9 December 2024. No casualties and injured reported from the attack.
Sources: en.wikipedia.org
Chyle (; from Greek χυλός (chylos) 'chyle') is a milky bodily fluid consisting of lymph and emulsified fats, or free fatty acids (FFAs). It is formed in the small intestine during digestion of fatty foods, and taken up by lymph vessels specifically known as lacteals. The lipids in the chyle are colloidally suspended in chylomicrons. Its principal role is to carry dietary fats and fat-soluble vitamins from the intestine into the venous circulation after digestion.
=== Prader–Willi syndrome === Carbetocin was under development in an intranasal formulation for the treatment of Prader–Willi syndrome (PWS). It was variously developed by Ferring Pharmaceuticals, Levo Therapeutics, and Acadia Pharmaceuticals and had developmental code names including ACP-101, FE-992097, and LV-101. The drug reached and completed multiple phase 3 clinical trials for PWS prior to the discontinuation of its development in October 2025. It was discontinued due to lack of effectiveness.
Aspergillus luchuensis (synonym Aspergillus awamori, Aspergillus inuii, Aspergillus nakazawai and Aspergillus coreanus, クロコウジキン / 黒麹菌 'kuro kōji-kin') Aspergillus niger (synonym Aspergillus batatae, Aspergillus aureus or Aspergillus foetidus, Aspergillus miyakoensis and Aspergillus usamii including A. usamii mut. shirousamii) Aspergillus tubingensis (synonym Aspergillus saitoi and A. saitoi var. kagoshimaensis) White kōji (Aspergillus kawachii) is an albino variant of Aspergillus luchuensis. It is typically used in the production of shōchū.
Type 2 diabetes is due to insulin resistance. As the disease progresses, there is often an increase of insulin production by beta cells, leading to a higher level of insulin in the blood (hyperinsulinemia), but the increased level of insulin is eventually insufficient to control the glucose concentration. Insulin resistance refers to the inability of cells to respond adequately to normal levels of insulin, at the molecular level of pathological mechanism, this is typically due to impairment of the insulin signal transduction pathway—specifically, aberrant inhibition of one or more proximal components in the signaling cascade downstream of the insulin receptor, such as the insulin receptor itself, insulin receptor substrate (IRS) proteins, or AKT. Insulin resistance occurs within the muscles, liver, and fat tissue. In the liver, insulin normally suppresses glucose release. However, in the setting of insulin resistance, the liver inappropriately releases glucose into the blood. The proportion of insulin resistance versus beta cell dysfunction differs among individuals, with some having primarily insulin resistance and only a minor defect in insulin secretion and others with slight insulin resistance and primarily a lack of insulin secretion. Importantly, insulin resistance also occurs within pancreatic islet β-cells themselves. Because normal β-cell function depends on intact insulin signaling within the β-cell, disruption of this pathway can impair insulin production and secretion, contributing to β-cell dysfunction of type 2 diabetes.
Sources: en.wikipedia.org
尚未。它仍处于临床研究阶段，任何监管批准都取决于正在进行的试验结果和提交审评。可公开获取的信息以试验注册和会议摘要为主。
司美格鲁肽主要靶向GLP-1受体，而瑞他鲁肽同时作用于GLP-1、GIP和胰高血糖素受体。这种三重机制旨在产生不同的代谢效应，但临床差异仍需头对头研究确认。
长期心血管结局、停药后维持效果、罕见不良事件和不同人群中的获益风险比尚未完全确定。完整三期数据和监管审评将影响结论。
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.